1. Home
  2. HKIT vs CRDL Comparison

HKIT vs CRDL Comparison

Compare HKIT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

N/A

Current Price

$2.09

Market Cap

121.6M

Sector

Technology

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.01

Market Cap

97.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HKIT
CRDL
Founded
1996
2017
Country
China
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.6M
97.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
HKIT
CRDL
Price
$2.09
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
559.6K
681.2K
Earning Date
04-08-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,812,901.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$0.77
52 Week High
$4.18
$1.59

Technical Indicators

Market Signals
Indicator
HKIT
CRDL
Relative Strength Index (RSI) 58.46 45.84
Support Level $1.42 $0.88
Resistance Level $1.53 $1.12
Average True Range (ATR) 0.24 0.08
MACD 0.07 0.01
Stochastic Oscillator 60.63 50.00

Price Performance

Historical Comparison
HKIT
CRDL

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: